BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mhibik M, Wiestner A, Sun C. Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL. Int J Mol Sci 2019;21:E68. [PMID: 31861854 DOI: 10.3390/ijms21010068] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Deaglio S, Hartmann TN. The Importance of Tumor-Host Interactions in Adult B-Cell Leukemias and Lymphomas. Int J Mol Sci 2020;21:E6915. [PMID: 32967158 DOI: 10.3390/ijms21186915] [Reference Citation Analysis]
2 Puzzolo MC, Del Giudice I, Peragine N, Mariglia P, De Propris MS, Cappelli LV, Trentin L, Reda G, Cuneo A, Molica S, Piciocchi A, Arena V, Mauro FR, Guarini A, Foà R. TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. Front Oncol 2021;11:637186. [PMID: 33937038 DOI: 10.3389/fonc.2021.637186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Roessner PM, Seiffert M. T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease? Leukemia 2020;34:2012-24. [PMID: 32457353 DOI: 10.1038/s41375-020-0873-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
4 Zhu S, Gokhale S, Jung J, Spirollari E, Tsai J, Arceo J, Wu BW, Victor E, Xie P. Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets - Beyond B Lymphocytes. Front Cell Dev Biol 2021;9:727531. [PMID: 34485307 DOI: 10.3389/fcell.2021.727531] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhu S, Jung J, Victor E, Arceo J, Gokhale S, Xie P. Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies. Front Oncol 2021;11:737943. [PMID: 34778053 DOI: 10.3389/fonc.2021.737943] [Reference Citation Analysis]
6 Dobaño-López C, Araujo-Ayala F, Serrat N, Valero JG, Pérez-Galán P. Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention. Cancers (Basel) 2021;13:641. [PMID: 33562694 DOI: 10.3390/cancers13040641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Vitale C, Boccellato E, Comba L, Jones R, Perutelli F, Griggio V, Coscia M. Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. Cancers (Basel) 2021;13:3856. [PMID: 34359757 DOI: 10.3390/cancers13153856] [Reference Citation Analysis]
8 Vlachonikola E, Stamatopoulos K, Chatzidimitriou A. T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia. Cancers (Basel) 2021;13:3255. [PMID: 34209724 DOI: 10.3390/cancers13133255] [Reference Citation Analysis]
9 Roussel M, Le KS, Granier C, Llamas Gutierrez F, Foucher E, Le Gallou S, Pangault C, Xerri L, Launay V, Lamy T, Tartour E, Olive D, Fest T. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. Blood Adv 2021;5:1816-29. [PMID: 33787861 DOI: 10.1182/bloodadvances.2020003080] [Reference Citation Analysis]
10 Mulder TA, Peña-Pérez L, Berglöf A, Meinke S, Estupiñán HY, Heimersson K, Zain R, Månsson R, Smith CIE, Palma M. Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia. Hemasphere 2021;5:e564. [PMID: 33912812 DOI: 10.1097/HS9.0000000000000564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Vlachonikola E, Stamatopoulos K, Chatzidimitriou A. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword. Front Immunol 2020;11:612244. [PMID: 33552073 DOI: 10.3389/fimmu.2020.612244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Palma M, Mulder TA, Österborg A. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. Front Immunol 2021;12:686768. [PMID: 34276674 DOI: 10.3389/fimmu.2021.686768] [Reference Citation Analysis]
13 Jacobs CF, Eldering E, Kater AP. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Adv 2021;5:913-25. [PMID: 33560402 DOI: 10.1182/bloodadvances.2020003768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yang S, Huang X, Gale RP. Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells. Blood Rev 2021;:100884. [PMID: 34489116 DOI: 10.1016/j.blre.2021.100884] [Reference Citation Analysis]
15 Kulumani Mahadevan LS, Ozdemirli M. Subcutaneous panniculitis-like T cell lymphoma arising in association with chronic lymphocytic leukaemia. BMJ Case Rep 2021;14:e243490. [PMID: 34580127 DOI: 10.1136/bcr-2021-243490] [Reference Citation Analysis]
16 McDonald C, Xanthopoulos C, Kostareli E. The role of Bruton's tyrosine kinase in the immune system and disease. Immunology 2021;164:722-36. [PMID: 34534359 DOI: 10.1111/imm.13416] [Cited by in F6Publishing: 1] [Reference Citation Analysis]